Brief Communication: Maternal Plasma Autoantibodies Screening in Fetal Down Syndrome
Imbalance in the metabolites levels which can potentially be related to certain fetal chromosomal abnormalities can stimulate mother’s immune response to produce autoantibodies directed against proteins. The aim of the study was to determine the concentration of 9000 autoantibodies in maternal plasm...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2016/9362169 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849304630351101952 |
|---|---|
| author | Karol Charkiewicz Monika Zbucka-Kretowska Joanna Goscik Slawomir Wolczynski Adam Lemancewicz Piotr Laudanski |
| author_facet | Karol Charkiewicz Monika Zbucka-Kretowska Joanna Goscik Slawomir Wolczynski Adam Lemancewicz Piotr Laudanski |
| author_sort | Karol Charkiewicz |
| collection | DOAJ |
| description | Imbalance in the metabolites levels which can potentially be related to certain fetal chromosomal abnormalities can stimulate mother’s immune response to produce autoantibodies directed against proteins. The aim of the study was to determine the concentration of 9000 autoantibodies in maternal plasma to detect fetal Down syndrome. Method. We performed 190 amniocenteses and found 10 patients with confirmed fetal Down syndrome (15th–18th weeks of gestation). For the purpose of our control we chose 11 women without confirmed chromosomal aberration. To assess the expression of autoantibodies in the blood plasma, we used a protein microarray, which allows for simultaneous determination of 9000 proteins per sample. Results. We revealed 213 statistically significant autoantibodies, whose expression decreased or increased in the study group with fetal Down syndrome. The second step was to create a classifier of Down syndrome pregnancy, which includes 14 antibodies. The predictive value of the classifier (specificity and sensitivity) is 100%, classification errors, 0%, cross-validation errors, 0%. Conclusion. Our findings suggest that the autoantibodies may play a role in the pathophysiology of Down syndrome pregnancy. Defining their potential as biochemical markers of Down syndrome pregnancy requires further investigation on larger group of patients. |
| format | Article |
| id | doaj-art-3bb3d8d40a594d9c887c2499bd6e4483 |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-3bb3d8d40a594d9c887c2499bd6e44832025-08-20T03:55:41ZengWileyJournal of Immunology Research2314-88612314-71562016-01-01201610.1155/2016/93621699362169Brief Communication: Maternal Plasma Autoantibodies Screening in Fetal Down SyndromeKarol Charkiewicz0Monika Zbucka-Kretowska1Joanna Goscik2Slawomir Wolczynski3Adam Lemancewicz4Piotr Laudanski5Department of Perinatology and Obstetrics, Medical University of Bialystok, Marii Sklodowskiej-Curie 24a, 15-276 Bialystok, PolandDepartment of Reproduction and Gynecological Endocrinology, Medical University of Bialystok, Marii Sklodowskiej-Curie 24a, 15-276 Bialystok, PolandFaculty of Computer Science, Bialystok University of Technology, Wiejska 45A, 15-351 Bialystok, PolandDepartment of Reproduction and Gynecological Endocrinology, Medical University of Bialystok, Marii Sklodowskiej-Curie 24a, 15-276 Bialystok, PolandDepartment of Perinatology and Obstetrics, Medical University of Bialystok, Marii Sklodowskiej-Curie 24a, 15-276 Bialystok, PolandDepartment of Perinatology and Obstetrics, Medical University of Bialystok, Marii Sklodowskiej-Curie 24a, 15-276 Bialystok, PolandImbalance in the metabolites levels which can potentially be related to certain fetal chromosomal abnormalities can stimulate mother’s immune response to produce autoantibodies directed against proteins. The aim of the study was to determine the concentration of 9000 autoantibodies in maternal plasma to detect fetal Down syndrome. Method. We performed 190 amniocenteses and found 10 patients with confirmed fetal Down syndrome (15th–18th weeks of gestation). For the purpose of our control we chose 11 women without confirmed chromosomal aberration. To assess the expression of autoantibodies in the blood plasma, we used a protein microarray, which allows for simultaneous determination of 9000 proteins per sample. Results. We revealed 213 statistically significant autoantibodies, whose expression decreased or increased in the study group with fetal Down syndrome. The second step was to create a classifier of Down syndrome pregnancy, which includes 14 antibodies. The predictive value of the classifier (specificity and sensitivity) is 100%, classification errors, 0%, cross-validation errors, 0%. Conclusion. Our findings suggest that the autoantibodies may play a role in the pathophysiology of Down syndrome pregnancy. Defining their potential as biochemical markers of Down syndrome pregnancy requires further investigation on larger group of patients.http://dx.doi.org/10.1155/2016/9362169 |
| spellingShingle | Karol Charkiewicz Monika Zbucka-Kretowska Joanna Goscik Slawomir Wolczynski Adam Lemancewicz Piotr Laudanski Brief Communication: Maternal Plasma Autoantibodies Screening in Fetal Down Syndrome Journal of Immunology Research |
| title | Brief Communication: Maternal Plasma Autoantibodies Screening in Fetal Down Syndrome |
| title_full | Brief Communication: Maternal Plasma Autoantibodies Screening in Fetal Down Syndrome |
| title_fullStr | Brief Communication: Maternal Plasma Autoantibodies Screening in Fetal Down Syndrome |
| title_full_unstemmed | Brief Communication: Maternal Plasma Autoantibodies Screening in Fetal Down Syndrome |
| title_short | Brief Communication: Maternal Plasma Autoantibodies Screening in Fetal Down Syndrome |
| title_sort | brief communication maternal plasma autoantibodies screening in fetal down syndrome |
| url | http://dx.doi.org/10.1155/2016/9362169 |
| work_keys_str_mv | AT karolcharkiewicz briefcommunicationmaternalplasmaautoantibodiesscreeninginfetaldownsyndrome AT monikazbuckakretowska briefcommunicationmaternalplasmaautoantibodiesscreeninginfetaldownsyndrome AT joannagoscik briefcommunicationmaternalplasmaautoantibodiesscreeninginfetaldownsyndrome AT slawomirwolczynski briefcommunicationmaternalplasmaautoantibodiesscreeninginfetaldownsyndrome AT adamlemancewicz briefcommunicationmaternalplasmaautoantibodiesscreeninginfetaldownsyndrome AT piotrlaudanski briefcommunicationmaternalplasmaautoantibodiesscreeninginfetaldownsyndrome |